BR9916209A - Cadeia de receptor de citocina - Google Patents

Cadeia de receptor de citocina

Info

Publication number
BR9916209A
BR9916209A BR9916209-1A BR9916209A BR9916209A BR 9916209 A BR9916209 A BR 9916209A BR 9916209 A BR9916209 A BR 9916209A BR 9916209 A BR9916209 A BR 9916209A
Authority
BR
Brazil
Prior art keywords
receptor chain
cytokine receptor
receptors
methods
chain
Prior art date
Application number
BR9916209-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Mary Collins
Debra Donaldson
Lori Fitz
Tamlyn Neben
Matthewj Whitters
Clive Wood
Marsha Wills-Karp
Original Assignee
Genetics Inst
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22786499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9916209(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst, Univ Johns Hopkins filed Critical Genetics Inst
Publication of BR9916209A publication Critical patent/BR9916209A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9916209-1A 1998-12-14 1999-12-13 Cadeia de receptor de citocina BR9916209A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21133598A 1998-12-14 1998-12-14
PCT/US1999/029493 WO2000036103A1 (en) 1998-12-14 1999-12-13 Cytokine receptor chain

Publications (1)

Publication Number Publication Date
BR9916209A true BR9916209A (pt) 2001-12-26

Family

ID=22786499

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916209-1A BR9916209A (pt) 1998-12-14 1999-12-13 Cadeia de receptor de citocina

Country Status (16)

Country Link
US (1) US7507706B1 (enExample)
EP (1) EP1141286B1 (enExample)
JP (3) JP5519087B2 (enExample)
CN (2) CN1352686A (enExample)
AT (1) ATE342976T1 (enExample)
AU (1) AU780031B2 (enExample)
BR (1) BR9916209A (enExample)
CA (1) CA2356779C (enExample)
CY (1) CY1107657T1 (enExample)
DE (1) DE69933696T2 (enExample)
DK (1) DK1141286T3 (enExample)
ES (1) ES2277460T3 (enExample)
MX (1) MXPA01006006A (enExample)
NZ (1) NZ512942A (enExample)
PT (1) PT1141286E (enExample)
WO (1) WO2000036103A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
EP1333850B1 (en) * 2000-10-20 2008-08-20 Genetics Institute, Inc. Use of il-13 inhibitors for the treatment of tumors
JP2006516035A (ja) * 2003-01-17 2006-06-15 チルドレンズ ホスピタル メディカル センター アレルギー治療におけるｔｆｆ２、またはｔｆｆ２誘導剤の使用
US20040198686A1 (en) * 2003-01-18 2004-10-07 Rothenberg Marc Elliot Regulation of allergen induced gene
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004092404A2 (en) * 2003-04-11 2004-10-28 Wyeth Inhibitors of acidic mammalian chitinase as asthma therapeutics
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2008153790A2 (en) * 2007-05-29 2008-12-18 University Of Cincinnati Methods of modulating inflammation and compositions therefore
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
JP7657548B2 (ja) 2017-04-21 2025-04-07 エランコ・ユーエス・インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
WO1991009059A1 (en) 1989-12-20 1991-06-27 Schering Corporation Antibody antagonists of human interleukin-4
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5246701A (en) 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
HU217099B (hu) 1991-03-29 1999-11-29 Elf Sanofi Sa. Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
CN1127351C (zh) 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
ES2334408T3 (es) 1995-10-23 2010-03-09 Zenyth Operations Pty Ltd Receptor de hematopoyetina y secuencias geneticas que lo codifican.
FR2742156A1 (fr) * 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU2326097A (en) 1996-03-13 1997-10-01 Zymogenetics Inc. Cytokine-receptor expressed in testis cells
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
EP0812913A3 (en) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
AU6175696A (en) 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
CN1572325A (zh) 1997-01-10 2005-02-02 拜奥根Idec马萨诸塞公司 用抗cd40l化合物治疗狼疮性肾炎
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
GB9723553D0 (en) 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
WO2000078336A1 (en) 1999-06-21 2000-12-28 Genetics Institute, Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
WO2001023410A2 (en) 1999-09-28 2001-04-05 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 13 gene
JP2003511019A (ja) 1999-10-06 2003-03-25 ザ ペン ステート リサーチ ファウンデーション Ｉｌ１３変異体
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos

Also Published As

Publication number Publication date
CN1352686A (zh) 2002-06-05
EP1141286A4 (en) 2002-06-26
DK1141286T3 (da) 2007-02-19
JP2014113165A (ja) 2014-06-26
EP1141286A1 (en) 2001-10-10
CA2356779A1 (en) 2000-06-22
NZ512942A (en) 2004-01-30
CY1107657T1 (el) 2013-04-18
PT1141286E (pt) 2007-01-31
CN104611339A (zh) 2015-05-13
ES2277460T3 (es) 2007-07-01
EP1141286B1 (en) 2006-10-18
ATE342976T1 (de) 2006-11-15
MXPA01006006A (es) 2004-08-12
AU2177500A (en) 2000-07-03
WO2000036103A9 (en) 2002-04-11
DE69933696D1 (de) 2006-11-30
JP5519087B2 (ja) 2014-06-11
WO2000036103A1 (en) 2000-06-22
JP2003511007A (ja) 2003-03-25
US7507706B1 (en) 2009-03-24
JP2010263889A (ja) 2010-11-25
CA2356779C (en) 2012-03-13
AU780031B2 (en) 2005-02-24
DE69933696T2 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
ATE342976T1 (de) Cytokinrezeptor-kette
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
AU2002305450A1 (en) Proteomimetic compounds and methods
DK0910647T3 (da) Human DNase i hyperaktive varianter
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
IS4311A (is) Setin 1H-imíðazól, aðferð til framleiðslu þeirra og notkun þeirra
UA49796C2 (uk) Ангідрат пароксетин гідрохлориду, спосіб його одержання, сольвати пароксетин гідрохлориду, спосіб їх одержання, спосіб лікування та/або профілактики та фармацевтична композиція
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
NO963850D0 (no) Heterosykliske forbindelser, deres fremstilling og anvendelse
DE69831500T2 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
FI913592A7 (fi) Valmistustapoja verihiutaleiden aktivaation polypeptidi-inhibiittoreid en tuottamiseksi sekä menetelmiä, yhdistelmiä ja koostumuksia, joissa niitä käytetään
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
NO990913D0 (no) Naftylforbindelser, intermediater, sammensetninger og metoder for anvendelse
DK0811068T3 (da) Humane DNase I varianter
EP1009421A4 (en) PROCESS AND COMPOSITIONS FOR IMPROVED Wounds Healing
UA33041A (uk) Спосіб остеосинтезу переломів виросту плечової кістки
MX9704618A (es) Receptor de la interlucina-11 humana.
PT1169054E (pt) Produtos e metodos para tratar doencas relacionadas com ptp lar
MD599B2 (en) Method for combined osteorrhaphy of tubular fractured fragments

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]